Effect of statins on cardiovascular events in patients with mild to moderate chronic kidney disease: a systematic review and meta-analysis of randomized clinical trials

Table 6 Subgroup analysis for the effect of statin therapy on cardiovascular death

Subgroup	Value	Reference	Statin	Control	Relative risk (95% CI)	p value	Heterogeneity	p value for heterogeneity
			(Event/total)	(Event/total)
Mean Age	> = 65	24,25	76/1425	99/1479	0.79 [0.59, 1.06]	0.114	0%	0.81
	<65	29, 31, 32,34	4/480	5/477	0.83 [0.24, 2.96]	0.778	0%	0.53
Cardiovascular History	Yes	29,31,34	76/1280	98/1230	0.80 [0.60, 1.07]	0.126	0%	0.69
	No	25,32	0/192	2/205	0.35 [0.04, 3.28]	0.354	0%	0.96
Baseline Creatinine	> = 1.5	25,29	17/333	28/339	0.63 [0.35, 1.12]	0.116	0%	0.68
	<1.5	24, 31,32,34	63/1572	76/1617	0.85 [0.62, 1.18]	0.338	0%	0.94
LDL Cholesterol Lowering	> = 30%	29	17/286	27/293	0.65 [0.36, 1.16]	0.142	-	-
	<30%	24,25,32	4/625	6/636	0.75 [0.23, 2.42]	0.625	0%	0.73
Follow-up time	> = 3	24, 29,31,32,34	80/1858	103/1910	0.80 [0.60, 1.06]	0.122	0%	0.90
	<3	25	0/47	1/46	0.33 [0.01, 7.81]	0.489	-	-

ISSN: 1471-2261